These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 16454534

  • 21. [Which patient is a candidate for treatment with efalizumab and why?].
    Puig L.
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():51-61. PubMed ID: 18341853
    [Abstract] [Full Text] [Related]

  • 22. The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder.
    Philipp S, Wolk K, Kreutzer S, Wallace E, Ludwig N, Roewert J, Höflich C, Volk HD, Sterry W, Sabat R.
    Expert Opin Ther Targets; 2006 Dec; 10(6):817-31. PubMed ID: 17105370
    [Abstract] [Full Text] [Related]

  • 23. Is there truly a risk of lymphoma from biologic therapies?
    Dommasch E, Gelfand JM.
    Dermatol Ther; 2009 Dec; 22(5):418-30. PubMed ID: 19845719
    [Abstract] [Full Text] [Related]

  • 24. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
    Alwawi EA, Krulig E, Gordon KB.
    Dermatol Ther; 2009 Dec; 22(5):431-40. PubMed ID: 19845720
    [Abstract] [Full Text] [Related]

  • 25. Psoriasis treatment: current and emerging directed therapies.
    Winterfield LS, Menter A, Gordon K, Gottlieb A.
    Ann Rheum Dis; 2005 Mar; 64 Suppl 2(Suppl 2):ii87-90; discussion ii91-2. PubMed ID: 15708946
    [Abstract] [Full Text] [Related]

  • 26. Treatment of psoriasis and psoriatic arthritis.
    Papoutsaki M, Costanzo A.
    BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
    [Abstract] [Full Text] [Related]

  • 27. Long-term data in the treatment of psoriasis.
    Thaçi D.
    Br J Dermatol; 2008 Aug; 159 Suppl 2():18-24. PubMed ID: 18700911
    [Abstract] [Full Text] [Related]

  • 28. Biologic therapy in psoriasis: perspectives on associated risks and patient management.
    Papp KA, Dekoven J, Parsons L, Pirzada S, Robern M, Robertson L, Tan JK.
    J Cutan Med Surg; 2012 Aug; 16(3):153-68. PubMed ID: 22713438
    [Abstract] [Full Text] [Related]

  • 29. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
    Busard CI, Cohen AD, Wolf P, Gkalpakiotis S, Cazzaniga S, Stern RS, Hutten BA, Feldhamer I, Quehenberger F, Lichem R, Kojanova M, Adenubiova E, Addis A, Naldi L, Spuls PI.
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):245-253. PubMed ID: 28898541
    [Abstract] [Full Text] [Related]

  • 30. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
    Wcisło-Dziadecka D, Zbiciak-Nylec M, Brzezińska-Wcisło L, Mazurek U.
    Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
    [Abstract] [Full Text] [Related]

  • 31. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
    Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, Hsu S, Weinberg JM.
    J Am Acad Dermatol; 2014 Jan; 70(1):168-77. PubMed ID: 24184141
    [Abstract] [Full Text] [Related]

  • 32. Classical to current approach for treatment of psoriasis: a review.
    Rahman M, Alam K, Ahmad MZ, Gupta G, Afzal M, Akhter S, Kazmi I, Jyoti, Ahmad FJ, Anwar F.
    Endocr Metab Immune Disord Drug Targets; 2012 Sep; 12(3):287-302. PubMed ID: 22463723
    [Abstract] [Full Text] [Related]

  • 33. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients.
    Brunasso AM, Puntoni M, Salvini C, Delfino C, Curcic P, Gulia A, Massone C.
    Acta Derm Venereol; 2011 Jan; 91(1):44-9. PubMed ID: 21088813
    [Abstract] [Full Text] [Related]

  • 34. [Clinical experience with efalizumab in the Hospital of Cruces].
    Martínez de Lagrán Z, González Hermosa MR, Díaz-Pérez JL.
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():74-81. PubMed ID: 18341856
    [Abstract] [Full Text] [Related]

  • 35. [The lymphocyte: protagonism in the new era of the biological therapies].
    Gutiérrez M, Ruiz Carrascosa JC.
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():2-8. PubMed ID: 18341848
    [Abstract] [Full Text] [Related]

  • 36. Comparative tolerability of systemic treatments for plaque-type psoriasis.
    McClure SL, Valentine J, Gordon KB.
    Drug Saf; 2002 Jan; 25(13):913-27. PubMed ID: 12381213
    [Abstract] [Full Text] [Related]

  • 37. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
    Gan EY, Chong WS, Tey HL.
    BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094
    [Abstract] [Full Text] [Related]

  • 38. Adverse Reactions to Biologics in Psoriasis.
    Lockwood SJ, Prens LM, Kimball AB.
    Curr Probl Dermatol; 2018 Aug; 53():1-14. PubMed ID: 29131033
    [Abstract] [Full Text] [Related]

  • 39. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH.
    Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
    [Abstract] [Full Text] [Related]

  • 40. Safety of conventional systemic agents and biologic agents in the treatment of psoriasis.
    Bissonnette R, Ho V, Langley RG.
    J Cutan Med Surg; 2009 Jun; 13 Suppl 2():S67-76. PubMed ID: 19799829
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.